Miriam Freimer, MD
Neurology · Columbus, OHNPI 1659455863
Payments from drug & device makers
Across 421 payments — averaging $6021.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$1M
- Alnylam Pharmaceuticals Inc.$453K
- Amicus Therapeutics, Inc.$269K
- Janssen Research & Development, LLC$158K
- Catalyst Pharmaceuticals, Inc.$154K
- Argenx US, Inc.$77K
- plus $384K from 12 others
What the payments were for
- Consulting fees$95,35291%
- Speaking & faculty fees$1,9502%
- Travel & lodging$4,8845%
- Food & beverage$2,6673%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 64 | $1,039,099 |
| Alnylam Pharmaceuticals Inc. | 152 | $452,985 |
| Amicus Therapeutics, Inc. | 52 | $269,152 |
| Janssen Research & Development, LLC | 19 | $158,415 |
| Catalyst Pharmaceuticals, Inc. | 12 | $154,025 |
| Argenx US, Inc. | 29 | $77,268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $72,955 |
| Genentech, Inc. | 4 | $62,682 |
| Novartis | 2 | $58,010 |
| UCB, Inc. | 43 | $54,977 |
| UCB Biosciences Inc. | 7 | $44,441 |
| Grifols Therapeutics LLC | 6 | $35,056 |
| Pfizer | 1 | $22,925 |
| UCB GmbH | 1 | $14,081 |
| AstraZeneca | 5 | $10,735 |
| Octapharma USA, Inc. | 1 | $3,780 |
| Janssen Scientific Affairs, LLC | 3 | $2,324 |
| CSL Behring | 1 | $1,950 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,534,860 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 21 | $1,108,483 |
| ZilbrysqZilucoplan Sodium | 25 | $1,028,653 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 40 | $805,565 |
| VyvgartEfgartigimod Alfa-Fcab | 12 | $529,049 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $164,808 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $52,218 |
| Mycophenolate Mofetil | 161 | $19,358 |
| Pyridostigmine Bromide | 117 | $10,516 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 14 | $6,047 |
| Albuterol Sulfate | 14 | $3,809 |
| Prednisone | 156 | $860 |
| Sodium Chloride0.9 % Sodium Chloride | 38 | $294 |
| Gabapentin | 27 | $203 |
| Tizanidine Hcl | 11 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $154,025 | $1,108,48321 claims |
| UCB, Inc.Zilbrysq | $54,977 | $1,028,65325 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $72,955 | $805,56540 claims |
| Argenx US, Inc.Vyvgart | $77,268 | $529,04912 claims |
| PfizerPanzyga | $22,925 | $164,80813 claims |
| CSL BehringPrivigen | $1,950 | $52,21814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 702 neurology providers in Ohio.
Other neurology in Columbus
- Jerry MendellColumbus$11.5M
- Douglas ScharreColumbus$6.8M
- Aaron BosterColumbus$6.3M
- Jacqueline NicholasColumbus$4.3M
- Pierre GiglioColumbus$2M
- Kenneth MankowskiColumbus$1.6M
- Tirisham GyangColumbus$1.5M
- Geoffrey EubankColumbus$1.4M
- Bakri ElsheikhColumbus$918K
- Brendan KelleyColumbus$880K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.